Fighting the FDA’s Final Rule on LDTs
CEO Laurie Menser discusses the Association for Molecular Pathology’s court case against the FDA’s rule on laboratory-developed tests.
CEO Laurie Menser discusses the Association for Molecular Pathology’s court case against the FDA’s rule on laboratory-developed tests.
From - G2 Compliance Advisor
SITUATION
Fictional Med (FM), a large physician-owned clinic, is one of your lab's biggest customers. So your heart sinks when…
From - G2 Compliance Advisor
The government agency that runs the Medicare program failed to follow a congressional directive to implement a market-based laboratory payment system…
By Mike O'Brien bio
Your news feed, like mine, has exploded with references to someone named Harvey Weinstein for the past few weeks. What's up? Weinstein is…
By Mike O'Brien bio
Here is my periodic update prepared for interested HR professionals trying to deal with the complex American employment laws…
From - G2 Compliance Advisor
Despite the PAMA cloud overhanging the laboratory industry, G2's 35th annual Lab Institute conference (Washington D.C.; Oct. 25-27) ended on an optimistic note with…
From - G2 Compliance Advisor
The first two keynote speakers at G2 Intelligence's 2017 Laboratory Institute (Washington D.C.; Oct. 25-27) took a forward glance at how…
From - G2 Compliance Advisor
There are many benefits laboratories can't provide to beneficiaries or referral sources without running afoul of the Anti-Kickback Statute. New changes to safe harbor regulations, however…